EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Discovery of novel and highly potent XIAP-targeted peptide inhibitors using virtual screening

Xiaoliang Wang, Mengting Lou, Yuting Wang, Miao-Miao Niu, Dongli Zhang

Journal of Enzyme Inhibition and Medicinal Chemistry · 2026

DOI: 10.1080/14756366.2026.2613518 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Enzyme Inhibition and Medicinal Chemistry, 2026. Verfasst von Xiaoliang Wang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Proctology, Taizhou Hospital of Traditional Chinese Medicine, Taizhou, Jiangsu, China. Hauptthemen laut MEDLINE: X-Linked Inhibitor of Apoptosis Protein, Antineoplastic Agents, Peptides, Drug Discovery. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lung cancer, a globally prevalent fatal malignancy, remains a major therapeutic challenge. X-linked inhibitor of apoptosis protein (XIAP) is overexpressed in various cancers, driving uncontrolled proliferation, while its specific inhibition suppresses tumour growth. Through virtual screening, we identified five novel candidate peptides (Peptides 1-5) with picomolar-level inhibitory activity. Peptide-5 showed the highest binding affinity (Kd = 10.2 ± 0.5 pM), and FP assay indicated that Peptide-5 competitively binds the BIR3 domain of XIAP against caspase-9. Molecular dynamics simulations confirmed the structural stability of its complex with XIAP. Meanwhile, Peptide-5 showed good serum and metabolic stability, as well as favourable cellular permeability. Notably, Peptide-5 exhibited potent antiproliferative activity against various tumour cells with no obvious toxicity to normal cells. Peptide-5 potentially activates apoptotic signalling through modulating the Bcl-2/Bax mRNA expression. In summary, our study confirms that Peptide-5 is a highly potent and promising XIAP-targeted inhibitor for the treatment of cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

X-Linked Inhibitor of Apoptosis ProteinAntineoplastic AgentsPeptidesDrug DiscoveryHumansCell ProliferationDrug Screening Assays, AntitumorStructure-Activity RelationshipDose-Response Relationship, DrugMolecular StructureDrug Evaluation, PreclinicalApoptosisMolecular Docking Simulation

Stichwörter der Autor:innen

X-linked inhibitor of apoptosis protein (XIAP)lung cancermolecular dockingvirtual screening

Substanzen

X-Linked Inhibitor of Apoptosis ProteinXIAP protein, humanAntineoplastic AgentsPeptides

Autor:innen und Institutionen

  • Department of Proctology, Taizhou Hospital of Traditional Chinese Medicine, Taizhou, Jiangsu, China.
  • Department of Pharmaceutical Analysis, China Pharmaceutical University, Nanjing, China.
  • Department of Gastroenterology, Taizhou School of Clinical Medicine, The Affiliated Taizhou People's Hospital of Nanjing Medical University, Taizhou, Jiangsu, China.

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Wang, X., Lou, M., Wang, Y., Niu, M. M., & Zhang, D. (2026). Discovery of novel and highly potent XIAP-targeted peptide inhibitors using virtual screening. Journal of Enzyme Inhibition and Medicinal Chemistry. https://doi.org/10.1080/14756366.2026.2613518

Vancouver

Wang X, Lou M, Wang Y, Niu MM, Zhang D. Discovery of novel and highly potent XIAP-targeted peptide inhibitors using virtual screening. Journal of Enzyme Inhibition and Medicinal Chemistry. 2026. doi:10.1080/14756366.2026.2613518

BibTeX
@article{Wang2026,
  author = {Wang, Xiaoliang and Lou, Mengting and Wang, Yuting and Niu, Miao-Miao and Zhang, Dongli},
  title = {Discovery of novel and highly potent XIAP-targeted peptide inhibitors using virtual screening},
  journal = {Journal of Enzyme Inhibition and Medicinal Chemistry},
  year = {2026},
  doi = {10.1080/14756366.2026.2613518}
}
Kostenlos starten →